These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 29469177)

  • 41. Differential Effects of Levosimendan and Dobutamine on Glomerular Filtration Rate in Patients With Heart Failure and Renal Impairment:A Randomized Double-Blind Controlled Trial.
    Lannemyr L; Ricksten SE; Rundqvist B; Andersson B; Bartfay SE; Ljungman C; Dahlberg P; Bergh N; Hjalmarsson C; Gilljam T; Bollano E; Karason K
    J Am Heart Assoc; 2018 Aug; 7(16):e008455. PubMed ID: 30369310
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of levosimendan without loading dose on systolic and diastolic function in patients with end-stage heart failure.
    Lunghetti S; Palmerini E; Urselli R; Maffei S; Guarino E; Focardi M; Mondillo S; Favilli R
    Cardiol J; 2011; 18(5):532-7. PubMed ID: 21947989
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial.
    Cleland JG; Takala A; Apajasalo M; Zethraeus N; Kobelt G
    Eur J Heart Fail; 2003 Jan; 5(1):101-8. PubMed ID: 12559222
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical pharmacology of levosimendan.
    Antila S; Sundberg S; Lehtonen LA
    Clin Pharmacokinet; 2007; 46(7):535-52. PubMed ID: 17596101
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Myocardial efficiency during levosimendan infusion in congestive heart failure.
    Ukkonen H; Saraste M; Akkila J; Knuuti J; Karanko M; Iida H; Lehikoinen P; Någren K; Lehtonen L; Voipio-Pulkki LM
    Clin Pharmacol Ther; 2000 Nov; 68(5):522-31. PubMed ID: 11103755
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Levosimendan: a new inodilatory drug for the treatment of decompensated heart failure.
    Kivikko M; Lehtonen L
    Curr Pharm Des; 2005; 11(4):435-55. PubMed ID: 15725064
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure.
    Ponikowski P; Mitrovic V; Ruda M; Fernandez A; Voors AA; Vishnevsky A; Cotter G; Milo O; Laessing U; Zhang Y; Dahlke M; Zymlinski R; Metra M
    Eur Heart J; 2014 Feb; 35(7):431-41. PubMed ID: 24255129
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Repetitive use of LEvosimendan in Ambulatory Heart Failure patients (LEIA-HF) - The rationale and study design.
    Tycińska A; Gierlotka M; Bartuś S; Gąsior M; Główczyńska R; Grześk G; Jaguszewski M; Kasprzak JD; Kubica J; Legutko J; Leszek P; Nessler J; Pacileo G; Ponikowski P; Sobkowicz B; Stępińska J; Straburzyńska-Migaj E; Wojakowski W; Zawiślak B; Zymliński R;
    Adv Med Sci; 2022 Mar; 67(1):18-22. PubMed ID: 34656873
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ambulatory Intravenous Inotropic Support and or Levosimendan in Pediatric and Congenital Heart Failure: Safety, Survival, Improvement, or Transplantation.
    Apostolopoulou SC; Vagenakis GA; Tsoutsinos A; Kakava F; Rammos S
    Pediatr Cardiol; 2018 Oct; 39(7):1315-1322. PubMed ID: 29777282
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of three different regimens of intermittent inotrope infusions for end stage heart failure.
    Bonios MJ; Terrovitis JV; Drakos SG; Katsaros F; Pantsios C; Nanas SN; Kanakakis J; Alexopoulos G; Toumanidis S; Anastasiou-Nana M; Nanas JN
    Int J Cardiol; 2012 Sep; 159(3):225-9. PubMed ID: 21481958
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Levosimendan reduces plasma B-type natriuretic peptide and interleukin 6, and improves central hemodynamics in severe heart failure patients.
    Kyrzopoulos S; Adamopoulos S; Parissis JT; Rassias J; Kostakis G; Iliodromitis E; Degiannis D; Kremastinos DT
    Int J Cardiol; 2005 Mar; 99(3):409-13. PubMed ID: 15771921
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Application of levosimendan in acute heart failure patients with symptoms of low cardiac output: case series report].
    Biegus J; Zymliński R; Kulej K; Szachniewicz J; Banasiak W; Jankowska EA; Ponikowski P
    Kardiol Pol; 2013; 71(3):275-8. PubMed ID: 23575784
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Levosimedan improves hemodynamics functions without sympathetic activation in severe heart failure patients: direct evidence from sympathetic neural recording.
    Despas F; Trouillet C; Franchitto N; Labrunee M; Galinier M; Senard JM; Pathak A
    Acute Card Care; 2010 Mar; 12(1):25-30. PubMed ID: 19929264
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Levosimendan versus dobutamine in heart failure patients treated chronically with carvedilol.
    Duygu H; Turk U; Ozdogan O; Akyuz S; Kirilmaz B; Alioglu E; Gunduz R; Bozkaya YT; Turkoglu C; Payzin S
    Cardiovasc Ther; 2008; 26(3):182-8. PubMed ID: 18786088
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Levosimendan: a review of its use in the management of acute decompensated heart failure.
    Innes CA; Wagstaff AJ
    Drugs; 2003; 63(23):2651-71. PubMed ID: 14636085
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hemodynamic effects of a continuous infusion of levosimendan in critically ill patients with cardiogenic shock requiring catecholamines.
    Delle Karth G; Buberl A; Geppert A; Neunteufl T; Huelsmann M; Kopp C; Nikfardjam M; Berger R; Heinz G
    Acta Anaesthesiol Scand; 2003 Nov; 47(10):1251-6. PubMed ID: 14616323
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Levosimendan improves renal function in patients with acute decompensated heart failure: comparison with dobutamine.
    Yilmaz MB; Yalta K; Yontar C; Karadas F; Erdem A; Turgut OO; Yilmaz A; Tandogan I
    Cardiovasc Drugs Ther; 2007 Dec; 21(6):431-5. PubMed ID: 17952581
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Is levosimendan effective in paediatric heart failure and post-cardiac surgeries?
    Angadi U; Westrope C; Chowdhry MF
    Interact Cardiovasc Thorac Surg; 2013 Oct; 17(4):710-4. PubMed ID: 23832921
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting.
    Lilleberg J; Nieminen MS; Akkila J; Heikkilä L; Kuitunen A; Lehtonen L; Verkkala K; Mattila S; Salmenperä M
    Eur Heart J; 1998 Apr; 19(4):660-8. PubMed ID: 9597417
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Intermittent levosimendan improves mid-term survival in chronic heart failure patients: meta-analysis of randomised trials.
    Silvetti S; Greco T; Di Prima AL; Mucchetti M; de Lurdes CM; Pasin L; Scandroglio M; Landoni G; Zangrillo A
    Clin Res Cardiol; 2014 Jul; 103(7):505-13. PubMed ID: 24368740
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.